Digestive Diseases and Sciences

, Volume 58, Issue 12, pp 3620–3625

Clinical Outcomes of Hepatitis C Treated with Pegylated Interferon and Ribavirin via Telemedicine Consultation in Northern California

  • Lorenzo Rossaro
  • Cara Torruellas
  • Sandeep Dhaliwal
  • Jacqueline Botros
  • Guiselle Clark
  • Chin-Shang Li
  • Mia M. Minoletti
Original Article



Patients in rural communities are less likely to receive treatment for their hepatitis C (HCV) infection. Telemedicine (TM) consultation can close the gap of access to specialists in remote and under-served areas.


To determine treatment response and side-effect profiles among HCV patients treated with pegylated interferon and ribavirin via TM consultation in different rural locations in Northern California compared with patients treated in traditional hepatology office visits.


We performed a retrospective analysis of 80 HCV patients treated at different TM sites (TM, n = 40) and at the University of California Davis Hepatology Clinic (HC, n = 40) between 2006 and 2010, comparing baseline characteristics and clinical outcomes.


At baseline, response to therapy was similar for patients in both groups. Sustained virological response (SVR) was similar in both groups (TM: 55 vs. HC: 43 %; p = 0.36), and a higher proportion of patients treated via telemedicine completed treatment (TM: 78 vs. HC: 53 %; p = 0.03). TM patients had many more visits per week of therapy (TM: 0.61 vs. HC: 0.07; p < 0.001). Neutropenia, GI side effects, fatigue, depression, weight loss, insomnia, and skin rash were similar in both groups. For HC patients incidence of anemia was significantly higher (53 %) than for the TM group (25 %; p = 0.02).


The two groups had equivalent SVR. For the TM group therapy completion was superior and incidence of anemia was lower. This initial study suggests that, as a group, patients with HCV, can be safely and effectively treated via telemedicine.


Telemedicine Hepatitis C Interferon Ribavirin Medically under-served areas Rural communities 


  1. 1.
    Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271–278.PubMedCrossRefGoogle Scholar
  2. 2.
    Daniels D. Surveillance for acute viral hepatitis—United States, 2007. Source: morbidity and mortality weekly report. CDC Surveillance Summ [1546-0738]. 2009;58:1–27.Google Scholar
  3. 3.
    Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995–2004. Hepatology. 2008;47:1128–1135.PubMedCrossRefGoogle Scholar
  4. 4.
    Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.PubMedCrossRefGoogle Scholar
  5. 5.
    Verna EC, Brown RS Jr. Hepatitis C and liver transplantation. Clin Liver Dis. 2006;10:919.PubMedCrossRefGoogle Scholar
  6. 6.
    Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997–2006. Am J Transplant. 2008;8:958–976.PubMedCrossRefGoogle Scholar
  7. 7.
    Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Cost of hepatitis C. Arch Intern Med. 2001;161:22–31.CrossRefGoogle Scholar
  8. 8.
    Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47:1–39.Google Scholar
  9. 9.
    Rocca LG, Yawn BP, Wollan P, Kim WR. Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med. 2004;2:116–124.PubMedCrossRefGoogle Scholar
  10. 10.
    Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther. 2007;25:1153–1162.PubMedCrossRefGoogle Scholar
  11. 11.
    Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684.PubMedCrossRefGoogle Scholar
  12. 12.
    Kasahara A, Tanaka H, Okanoue T, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver related death. J Viral Hepat. 2004;11:148–156.PubMedCrossRefGoogle Scholar
  13. 13.
    Poodard F, McCone J, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.CrossRefGoogle Scholar
  14. 14.
    Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.PubMedCrossRefGoogle Scholar
  15. 15.
    Yawn BP, Wollan P, Gazzuola L, Kim WR. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract. 2002;51:135–140.PubMedGoogle Scholar
  16. 16.
    Rossaro L, Aoki C, Yuk J, Prosser C, Goforth J, Martinez F. The evaluation of patients with hepatitis C living in rural California via telemedicine. Telemed e-Health. 2008;14:1127–1129.CrossRefGoogle Scholar
  17. 17.
    Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Eng J Med. 2011;364:2199–2207.CrossRefGoogle Scholar
  18. 18.
    Rossaro L, Tran TP, Cole SL, Nesbitt TS. Telemedicine: improving access to care of hepatitis C. Pract Gastroenterol. 2003;17:21–22.Google Scholar
  19. 19.
    Torruellas C, Rossaro CC, Li C-S, Rossaro L. The use of telemedicine for the management of hepatitis C & the California telehealth network, advances in telemedicine. In: Graschew G, ed. Applications in Various Medical Disciplines and Geographical Regions. InTech; 2011. ISBN: 978-953-307-161-9. doi:10.5772/14451, modified).

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Lorenzo Rossaro
    • 1
  • Cara Torruellas
    • 1
  • Sandeep Dhaliwal
    • 1
  • Jacqueline Botros
    • 1
  • Guiselle Clark
    • 1
  • Chin-Shang Li
    • 1
  • Mia M. Minoletti
    • 1
  1. 1.University of California DavisSacramentoUSA

Personalised recommendations